Jack Stewart discusses SOR-C18 disruption of TRPV6
Jack Stewart, CSO of Soricimed Biopharma explains SOR-C13, a selective inhibitor of TRPV6, binds with affinity and disrupts how TRPV6 functions.
Author: Cancer-News
Added: 08/23/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Cancer | Cancer & Oncology